Fairvalue-Calculator Fairvalue-Calculator
EN DE

Ryvu Therapeutics S.A (RVU) Fair Value & Analysis

Healthcare · PL · Market cap 338M PLN

Price14.26 PLN
Fair Value10.48 PLN
Upside-26.5%
Quality95/100
Evidence: Low Range 7.86 PLN – 13.10 PLN

Fair value as of: Jun 24, 2026

Analysis

Ryvu Therapeutics S.A (RVU) currently trades at 14.26 PLN, while our model-based Fair Value estimate is 10.48 PLN — implying the stock looks roughly 26.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company's early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted t…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Ryvu Therapeutics S.A (RVU) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 10.48 PLN versus a price of 14.26 PLN — about −27% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RVU?
Our 21-model fair value for Ryvu Therapeutics S.A is 10.48 PLN (as of Jun 24, 2026), built from audited fundamentals. The current price is 14.26 PLN.
What is the quality score of RVU?
Ryvu Therapeutics S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.